基于薄膜干涉的免标记免疫分析法检测达雷妥尤单抗对血清蛋白电泳的干扰
本研究建立并验证了一种基于薄膜干涉(TFI)技术的免标记免疫分析法(LFIA),用于定量检测血清中达雷妥尤单抗(DARA)。该方法精密度CV在6.5%至11.6%之间,偏差-2.1%至10.1%,定量下限10 μg/ml,分析测量范围至1000 μg/ml。用于37例SPEP送检样本,检测结果与病历记录的DARA使用史100%一致,表明可识别DARA对SPEP的干扰。
要点
- TFI-LFIA可快速定量血清DARA,批内CV 6.5%–10.7%,批间CV 7.4%–11.6%。
- 定量下限10 μg/ml,分析测量范围10–1000 μg/ml。
- 37例SPEP样本检测与病历DARA使用史100%一致,可用于识别SPEP干扰。
核心结论
- 基于TFI的免标记免疫分析法能准确识别血清中的DARA,可用于识别DARA对SPEP检测的干扰。
研究设计与样本
- 方法学验证研究:建立基于薄膜干涉(TFI)的免标记免疫分析法(LFIA)定量血清DARA,并验证不精密度、准确度、定量下限和分析测量范围。
- 干扰评估使用一组蛋白样本及溶血、脂血、黄疸临床样本。
- 用该法检测37例送检SPEP的患者样本,并与病历记录的DARA使用史比较。
主要发现
- 批内CV为6.5%–10.7%,批间CV为7.4%–11.6%,偏差为-2.1%–10.1%。
- 定量下限为10 μg/ml(n=4,CV 9.8%),分析测量范围为定量下限至1000 μg/ml。
- 37例SPEP送检样本的LFIA结果与病历记录的DARA使用史100%一致。
关键数值与推荐
- 批内CV 6.5%–10.7%,批间CV 7.4%–11.6%,偏差-2.1%–10.1%。
- 定量下限10 μg/ml(n=4,CV 9.8%),分析测量范围10–1000 μg/ml。
临床怎么用
- 可采用TFI-LFIA快速定量血清DARA,辅助识别DARA在SPEPγ区形成的单克隆条带干扰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daratumumab (DARA) is a fully human anti-CD38 IgG1-κ monoclonal antibody drug used in the treatment of multiple myeloma (MM). While serum protein electrophoresis (SPEP) is an important assay for diagnosis and monitoring of patients with MM, DARA can appear in the γ-region as a single band and interfere with the interpretation of SPEP results. An approach to detect the interference is measuring the quantity of DARA in serum samples and assessing its impact on SPEP results. Immunoassays based on label-free technologies, i.e. label-free immunoassays (LFIA's), can achieve real-time immunometric measurement without attaching a reporter molecule (enzyme, fluorophore, etc.) to the immunocomplex. The recorded time course of the immunocomplex formation allows for quantitation on initial binding rate, which facilitates rapid measurement within a few minutes. Based on the thin-film interferometry (TFI) technology, a rapid LFIA was established for the quantitation of DARA in serum samples. METHODS: The TFI-based LFIA for DARA was validated for imprecision (CV), accuracy, limit of quantitation (LOQ), and analytical measurement range (AMR). Interference to the LFIA was evaluated using a group of protein samples, as well as hemolytic, lipemic, and icteric clinical samples. RESULTS: The precision of the TFI-based LFIA's for DARA ranged from 6.5% to 10.7% (within-run CV), and 7.4% to 11.6% (between-run CV), with a bias of -2.1% to 10.1%. The LOQ was 10 μg/ml (n = 4, CV 9.8%), with an AMR ranging from the LOQ to 1000 μg/ml. The LFIA was used to measure 37 patient samples submitted for SPEP testing. The LFIA results were 100% consistent with the history of DARA use as documented in the medical record. CONCLUSIONS: The TFI-based LFIA was successful at accurately identifying DARA in serum samples and can be used to identify DARA interference in SPEP testing. This work demonstrates the applicability of label-free technologies, particularly the TFI technology, to clinical diagnostic needs. Given the simplicity and the speed of the testing process, the TFI technology provides a unique testing approach for the measurement of proteins in clinical samples.
引用
- Luo YR, Chakraborty I, Zuk RF, et al. A thin-film interferometry-based label-free immunoassay for the detection of daratumumab interference in serum protein electrophoresis. Clin Chim Acta. 2019. PMID: 31883925. doi:10.1016/j.cca.2019.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。